Generalized anxiety disorder (GAD) is highly prevalent among adolescents. An early detection of individuals at risk may prevent later psychiatric condition. Genome-wide studies investigating single nucleotide polymorphisms (SNPs) concluded that a focus on epigenetic mechanisms, which mediate the impact of environmental factors, could more efficiently help the understanding of GAD pathogenesis. We investigated the relationship between epigenetic shifts in blood and the risk to develop GAD, evaluated by the Development and Well-Being Assessment (DAWBA) score, in 221 otherwise healthy adolescents. Our analysis focused specifically on methylation sites showing high inter-individual variation but low tissue-specific variation, in order to infer a potential correlation between results obtained in blood and brain. Two statistical methods were applied, 1) a linear model with limma and 2) a likelihood test followed by Bonferroni correction. Methylation findings were validated in a cohort of 160 adults applying logistic models against the outcome variable "anxiety treatment obtained in the past" and studied in a third cohort with regards to associated expression changes measured in monocytes. One CpG site showed 1% increased methylation in adolescents at high risk of GAD (cg16333992, p adj. = 0.028, estimate = 3.22), as confirmed in the second cohort (p = 0.031, estimate = 1.32). The identified and validated CpG site is located within the STK32B promoter region and its methylation level was positively associated with gene expression. Gene ontology analysis revealed that STK32B is involved in stress response and defense response. Our results provide evidence that shifts in DNA methylation are associated with a modulated risk profile for GAD in adolescence.
Introduction
There is a high prevalence of anxiety and mood disorders among adolescents (Polanczyk et al., 2015) . Compared to their healthy counterparts, adolescents at risk for anxiety disorders are two to three fold more likely to develop a diagnosable mental health condition (Naylor et al., 2012) or to show health-compromising behaviors such as substance abuse and suicide (Fergusson and Woodward, 2002) . One of the most common psychiatric illnesses shown in younger individuals is generalized anxiety disorder (GAD), a condition associated with many comorbidities and heavy costs to society. Extrinsic experiences are assumed to provoke changes at the epigenetic level, especially during adolescence, which consequently have the ability to modify the psychiatric phenotype (Mitchell et al., 2016) . However, the epigenetic regulation of GAD development is not yet understood. Epigenetic and transcriptional mechanisms that play a role in GAD pathogenesis are yet to be defined, which could allow for early and effective prevention strategies against GAD.
In adolescence, the difficulty to cope with stressful factors, e.g. social pressure, academic performance, family stability, together with a reprograming of distinct signaling mechanisms, leads to excessive worry and inability to control it (McLaughlin and Hatzenbuehler, 2009) . Genome-wide studies have shown that common single nucleotide polymorphisms (SNPs) explained only 7.2% of the variance in GAD symptoms, suggesting that demographic and lifestyle factors (e.g. age, diet, exercise) contribute to disease susceptibility and outcome to a significant extent (Davies et al., 2015; Dunn et al., 2017) . Different gene regulatory mechanisms, such as DNA methylation (DNAm) or histone variants as well as post-translational modifications orchestrate human brain development and may underpin the psychopathology of neuropsychiatric disorders. DNAm, the most studied epigenetic mechanism, has been shown to be highly modulated by environmental factors (Kofink et al., 2013; Rutten and Mill, 2009 ) and is furthermore cell type-and tissue-specific (Hardy et al., 2017) . Indeed, a large portion of the methylome varies greatly between tissues as a result of cell specialization and shows only limited differences between individuals (Davies et al., 2012) . Methylated cytosines in the CpG context can recruit proteins with repressive domains or block the binding of transcription factors at gene promoters, causing a decrease in gene expression.
Few studies have investigated the relationship between methylation patterns and GAD. Wang et al. performed a targeted analysis in peripheral blood, reveling higher methylation levels at the glucocorticoid receptor gene (NR3C1) in patients with GAD (Wang et al., 2017) . Recently, altered methylation levels at the ASB1 gene promoter were detected in an epigenome-wide association study (EWAS) in whole blood comparing severely anxious and healthy participants (Emeny et al., 2018) .
Given that blood is an easy accessible tissue, the majority of studies analyzing epigenetic changes in psychiatric disorders used blood methylation levels as a proxy for brain DNAm profiles (Cordova-Palomera et al., 2015; Ciuculete et al., 2017; Bostrom et al., 2017; Rukova et al., 2014) . Supporting this approach, tissue-specific epigenetic profiles have been recently characterized in the Encyclopedia of DNA Elements (ENCODE) and the NIH Epigenomics Roadmap projects to gain more knowledge about chromatin states and gene-gene interactions in different tissues (Ernst et al., 2011; Roadmap Epigenomics et al., 2015) . Additionally, previous studies analyzed the correlation between DNAm variation in blood and postmortem brain tissue (Walton et al., 2016; Davies et al., 2012; Hannon et al., 2015) . In the study performed by Walton et al. (2016) , 7.9% of the CpG sites showed a strong and significant correlation between blood and brain methylation patterns in 12 individuals. Moreover, using a larger sample (n = 122) and four brain regions (prefrontal cortex, entorhinal cortex, superior temporal gyrus and cerebellum), Hannon et al. (2015) concluded that some methylation sites show a greater inter-individual variation than the variation between tissues.
Our aim was to identify methylation patterns linked to the risk to develop GAD in adolescents. Importantly, we intended to reliably extrapolate our results obtained in blood to the brain. Therefore, we considered tissue-specific methylation signatures by focusing only on methylation sites for which inter-individual variation outweighs differences in brain-blood methylation. The identified and validated CpG sites and the associated genes were examined for their functional relevance in biological pathways using several different bioinformatics tools.
Methods

Discovery dataset
Our study comprised 221 non-related adolescents aged 14 to 16 years who were recruited between 2012 and 2014 in Uppsala, Sweden (see Supplementary File). DNAm analyses of the subjects were performed at two different time points, meaning that some adolescents were analyzed at time point 1, and some other adolescents at time point 2 (Ciuculete et al., 2017) . Measurements of both time points were considered in our discovery analyses in order to increase the analysis power. The psychiatric phenotype was assessed by the standardized DAWBA questionnaire (Goodman et al., 2000) and validated in a Brazilian sample (Fleitlich-Bilyk and Goodman, 2004) . The questionnaire allows generating in silico scores ranging between less than 0.1% to over 70% probability that an adolescent (aged 5-17 years) is characterized by anxiety disorders, depression, post-traumatic stress disorder, autism, separation anxiety disorder and obsessive compulsive disorder, based on DSM-IV and ICD-10 (Goodman et al., 2011) . The GAD DAWBA band consists of questions concerning specifically general anxiety, such as e.g. the level of worry about schoolwork, dying or own appearance and to what extent these worries are associated with physical symptoms. The study was approved by the Regional Ethics Committee in Uppsala and all participants gave their written informed consent.
Validation dataset
For validation analyses, an independent, published dataset stored in the Gene Expression Omnibus database (GEOD) was used (E-GEOD-72680). More details about this cohort can be found in Supplementary File. This dataset was used to confirm the epigenetic findings associated with elevated GAD risk in an adult cohort suffering from anxiety. Briefly, this cohort consisted mostly of females aged between 18 and 77 years, who were characterized by the use of drugs against anxiety in the medical history (Zannas et al., 2015) . Out of the 392 individuals originally present in the dataset, we excluded subjects with reported body mass index (BMI) higher than 30, in order to standardize the dataset for our study. A total of 160 individuals were thus included in the validation analysis.
Expression dataset
We used an additional independent open-access dataset (E-GEOD-56047) containing both transcriptomic and methylome data from CD14 + samples of 1202 participants (44-83 years-old) (Reynolds et al., 2014 ) (more details in Supplementary File). For our analyses, both methylation and expression data was checked for outliers using graphical visualization and were removed from further calculations. The dataset was used to investigate the effect of methylation shifts on gene expression.
Probe selection
Hannon et al. investigated the correlation between epigenetic patterns in whole blood and four different brain regions and identified 22,459 CpG loci for which tissue-specificity of methylation was minimal. Across these probes, individual differences explain more than 90% of the variance in DNA methylation at 16,285 (73%) sites. For the remaining ones (27%), inter-individual variation explained more than 50% of the total variance (see Supplementary File). These CpG sites fulfilled the following equation:
Where M tot is the measured methylation level, M indiv is the methylation level predicted by the individual and M tissue is the effect of tissue (blood or brain).
We considered only probes lying within ± 2000 base pairs (bp) from the transcriptional start site (TSS), as Wagner et al. demonstrated that DNA methylation and gene expression are closely related within this region (Wagner et al., 2014) . After the removal of probes with low detection p-value, a total of 13,156 loci were included in further analyses.
Data analysis and statistical tests
Data analysis was performed as summarized in the flow chart to answer three main questions: 1) Are there any differentially methylated probes between adolescents at high and low risk of GAD in blood?
Adolescents were grouped in individuals with low and high risk of GAD according to their scores defined by the DAWBA band ("genband"). A score below 15% was defined as "Low-risk" (category 0) (74.8%) and included the levels 0 (< 0.1%), 1 (≈0.5%) and 2 (≈3%) of the DAWBA generalized anxiety band. The individuals with levels 3 (≈15%), 4 (≈50%) and 5 (> 70%), having a risk higher than 15%, were assigned to the "High-risk" category (25.2%). For statistical analysis, a M-value was calculated at each site as the log 2 ratio of the intensities of methylated probe and unmethylated probe, which is more statistically valid for differential methylation analysis (Du et al., 2010) . Methylation values were corrected for cell-type composition (Ciuculete et al., 2017) . White blood cell type fractions, i.e. CD4 + and CD8 + T cells, monocytes (Mono), granulocytes (Gran), B cells (Bcell) and natural killer (NK) cells, were estimated based on an algorithm generated Houseman et al. (2012) . Association analyses were performed between M-value at each of the 13,156 CpG sites and the risk category, using the following covariates: age, sex, BMI, sub-analysis time point and the first two principal components associated with the most variable CpG sites, measured in terms of their 95% reference range (Ciuculete et al., 2017) . The sub-analysis time point variable refers to time point 1 or time point 2, depending on time the adolescents were analyzed. These linear regressions were run through the limma models in R, based on a moderated t-statistic previously deemed suitable for large-scale methylation studies (Smyth, 2004; Rask-Andersen et al., 2016) . Differentially methylated probes (DMPs) were considered significant after passing the stringent Bonferroni correction. To strengthen the results, a second statistical method, the likelihood ratio test, was applied. For this test, the lrtest function of the lmtest R package was used (Achim Zeileis, 2002) . The same covariates as the limma model were included and the Bonferroni correction was applied in order to correct for multiple testing. Two-tailed p-values < 0.05 were considered significant. Subsequently, the functional relevance of the identified DMPs was explored in two online databases by analyzing chromatin state and correlation of ten brain tissues and peripheral blood mononuclear primary cells (see Supplementary File) . Moreover, the genes that were annotated to the DMPs were examined for molecular interactions using the GeneMANIA plugin (Montojo et al., 2010) .
We used the molecular functional interaction database ConsensusPathDB (Kamburov et al., 2013) to identify gene ontology (GO)-enriched terms. The top 5% most nominally significant CpG sites identified by limma were annotated and the associated genes were analyzed for gene ontology. Only the gene clusters showing an overlap with the candidate genes ≥10 were considered. A q-value < 0.05 was evaluated as statistically significant.
2) Are the identified CpG sites associated with anxiety treatment in a separate blood sample?
To validate CpG sites associated with the DAWBA GAD scores, we tested whether those CpG loci are associated with the administration of therapeutics against anxiety in a separate sample of 160 individuals. DMPs were independently included in generalized linear models using the administration of anxiety treatment as binary dependent outcome variable (yes/no anxiety treatment). The models were adjusted for treatment for depression (yes/no). This covariate was identified as important based on an initial stepwise evaluation of the potential available confounders in a generalized linear model against the phenotype anxiety treatment. A nominal p-value < 0.05 was considered significant.
3) Are risk DMPs associated with gene expression levels in blood?
Lastly, we investigated to what extent methylation levels at the validated DMPs were associated with gene expression levels. Firstly, using the information about different batches, we corrected the available methylation data for this potential source of bias, using the combat function. Moreover, DNAm together with expression values were investigated for possible outliers using a boxplot representation and they were excluded from further analysis. Potential confounders for our statistical model investigating methylation values in relationship with expression data were determined with variance p-values. Each potential covariate, i.e. cell blood proportions (B-cells, T-cells, natural killer cells, and neutrophils), well position, age of the participant and the 'racegenderSite' variable, accounting for race, gender and study site, was independently included into the linear model. Only the variable 'racegenderSite' variable was significant (p = 0.008). We therefore included 'racegenderSite' variable as a covariate in the final model used for the association between M-values and gene expression.
Pyrosequencing
A subset of 60 individuals who had low DAWBA GAD band (n = 30) and high DAWBA GAD band (n = 30) were selected for pyrosequencing measurement. More details about the procedure can be found in the Supplementary File.
Post-hoc analysis
The STK32B gene variant rs1530609 was shown to be one of the top 5 SNPs to be associated with the risk to attempt suicide when suffering from depression (n = 257 cases vs 200 controls) in a genome-wide association study (Galfalvy et al., 2015) . To further understand whether the regulation of STK32B could be involved in suicide risk, methylation of STK32B was investigated in relationship with suicide risk in an openaccess cohort (GSE88890). A total of 20 depressed suicide cases and 20 non-psychiatric sudden death controls had methylation measurements from two regions of the cortex (Brodmann Area11(BA11), n = 40 and Brodmann Area 25 (BA25), n = 35). More information about this cohort can be found in (Murphy et al., 2017) . Neuronal proportions were calculated for all samples, using the Cell EpigenoType Specific mapper package in R (Guintivano et al., 2013) . A total of 14 CpG sites were selected within 2000 bp of the TSS of STK32B. The two brain regions were investigated separately, applying logistic regression models between suicide cases and controls. Methylation levels at the associated CpG sites were included as a quantitative independent variable. We included the same covariates as in the original published paper (Murphy et al., 2017) , i.e. age, gender and the neuronal proportions.
Results
DNA methylation and generalized anxiety disorder. Our workflow is illustrated in Fig. 1 . The characteristics of the 221 included adolescents are listed in Table 1 . Adolescents from the low-risk group were 3.5 months younger than adolescents from the high-risk group (15.42 ± 0.62 and 15.71 ± 0.65 years, p-value = 0.0059). The lowrisk and high-risk groups for GAD did not differ in BMI. The distribution of all DAWBA bands across the 221 samples, including the general DAWBA band, and the DAWBA bands for e.g. depression, panic disorder and other psychiatric diseases is displayed in Fig. S1 .
For subsequent analyses, we included 13,156 CpG sites within ± 2000 bp from TSS for which methylation levels were predicted to vary more between individuals than between tissues. The DAWBA scores of GAD band were used as independent binary variable for both tests. Using limma, 1327 CpG sites had a raw p-value < 0.05. The model was corrected for cell-type proportions, age, sex, BMI, sub-analysis time point and the first two principal components (Ciuculete et al., 2017) . The independent sample t-test showed that there was a significant difference between individuals at different risk for GAD regarding CD8+T (p = 9.28e-06), Bcell (p = 1.26e-09) and Gran (p = 0.04). Therefore, beta values were corrected for these differences including them as co-variates. As a result, the first two PCs were not correlated with the cell type fractions allowing the assumption that gathered results were not significantly influenced by cell type composition (Fig.  S2) . Only one CpG site passed the Bonferroni correction (cg16333992, logFC = 0.25, p raw. = 2.18e-06, p adj. = 0.028). Applying the likelihood test for the same CpG sites, 1437 CpG sites were detected to be nominally significant. All CpG sites identified by limma overlapped with the D.M. Ciuculete et al. Journal of Psychiatric Research 102 (2018) 44-51 ones identified by the likelihood test. After Bonferroni correction, one CpG site remained significant, i.e. cg16333992 (p raw. = 1.42e-06, p adj. = 0.018). Thus, cg16333992 was identified using both statistical approaches after correction for multiple testing. This CpG site displayed increased methylation in adolescents at high risk of GAD, showing a methylation difference of 1% between adolescents at high and low risk of GAD. The difference in methylation levels at this CpG site is illustrated in the boxplot in Fig. 2A . Validation of the CpG methylation variation in STK32B. The CpG site identified in the discovery sample (cg16333992) is located 70 bp upstream of the TSS of STK32B, and has very low methylation levels (3-9%). We evaluated this CpG site in an independent dataset of adults with a history of childhood trauma and a lifetime drug treatment against anxiety. Patients were 40.6 ± 14.0 years old (range 18-77), had a BMI of 25.2 ± 3.05 and were mostly female (n = 88 (55%)) (Supplementary Table 1 ). Out of 160 individuals, twelve individuals followed a treatment for anxiety disorders. Patients taking drugs against anxiety had higher reported childhood sexual abuse, bipolar disorder treatment, depression treatment and posttraumatic stress treatment, compared with patients not taking drugs against anxiety. We designed a logistic regression model consisting of anxiety treatment as the dependent outcome variable together with the M-values of cg16333992 and depression treatment (yes/no) that was an important confounder. Patients following anxiety treatment had a 1% higher mean methylation at cg16333992 (p = 0.031, β = 1.32) compared with controls. The detected methylation differences at the identified CpG site treatment are comparable to methylation shifts identified for adolescents at high risk of GAD (Fig. 2B) .
Methylation at cg16333992 is associated with mRNA expression of STK32B. We tested a possible association between methylation at cg16333992 and mRNA expression of STK32B. Four outliers for methylation at cg16333992 and two outliers for STK32B gene expression were removed from the analysis. We fitted a linear model on the mRNA expression levels of STK32B, using the M-values at cg16333992 as the main variable of interest, adjusting for race, sex and study site. Methylation at cg16333992 was positively associated with expression levels (p = 0.0018), showing a rather small effect size (β = 0.03). Of note, none of the cell-type proportions modulated the association between the methylation values at cg16333992 and expression levels of STK32B mRNA.
Functional relevance of cg16333992 and STK32B. Cg16333992 has not been characterized before, so we sought to investigate its regulatory effect on the annotated gene. In line with our hypothesis regarding the overlap between blood and brain DNAm functional relevance of the analyzed CpG sites, cg16333992 is located within the active flanking/bivalent poised TSS promoter region of STK32B in Fig. 1 . Flowchart of analysis. In a cohort of 221 adolescents, the methylation patterns at 22,459 CpG sites were investigated against generalized anxiety disoder (GAD). These DNA sites were shown to be more predicted by individual variation than by brain or blood tissue methylation signature. The identified CpG sites were replicated in an independent adult cohort of 160 adults, where treatment for anxiety disorder was used as independent outcome variable. The association between methylation shifts and gene expression was investigated in 1196 individuals belonging to a population based cohort. In a last step, the functional relevance of methylation loci and annotated genes was examined. Continuous variables are shown as mean ± standard deviation (SD) or number (percentage). *All listed DAWBA bands refer to individuals with low risk (defined by DAWBA bands = 0, 1 or 2) of e.g. general band, depression, panic disorder. **Two-tailed analysis tests the difference between the "Low-risk" and "Highrisk" group using the Student's t-test for continuous variables and the Chisquare test for categorical variables (Likelihood ratio). Individuals with a general DAWBA psychiatric risk score below 15% were defined as "Low-risk" and included 0 (< 0.1%), 1 (≈0.5%) and 2 (≈3%) level bands of the DAWBA generalized anxiety score. Individuals with level bands 3 (≈15%), 4 (≈50%) and 5 (> 70%), having a risk higher than 15%, were assigned to the "High-risk" category. Abbreviations: BMI, body mass index; DAWBA, Development and Well-Being Assessment. BrainITL, brain inferior temporal lobe; BrainDPC, brain dorsolateral prefrontal cortex; BrainSN, brain substantia nigra; BrainAG, brain angular gyrus; PBMC, peripheral blood mononuclear primary cells. B) Gene analysis using GeneMANIA. Black circles represent genes (n = 20) predicted by GeneMANIA based on genetic and physical interactions, shared protein domains together with protein co-expression data. This analysis shows a potential biological network around our identified gene associated with increased GAD risk. C) Significant gene ontology (GO) terms. The analysis is based on the top 5% most significant genes (n = 66) found in relationship with GAD risk. Circles represent GO terms that survived FDR correction and contain at least one gene. The X axis shows -log(10) p-values. The color of the circles indicates the significance level, where the darker ones represent the most significant GO terms. The circle size gives information about the gene number included in the pathway. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) seven different brain tissues: brain angular gyrus, brain anterior caudate, brain cingulate gyrus, brain hippocampus, brain inferior temporal lobe, brain substantia nigra and peripheral blood mononuclear primary cells, according data from the ENCODE database (Fig. 3A) . Moreover, using the BECon tool, correlations between blood and BA7 (50-75% positive) and BA20 (50-75% negative) brain tissues were identified.
In addition we performed a GO analysis including the 5% top most nominally significant genes that showed methylation associations with the GAD DAWBA band. The analysis indicated that most of the identified genes are enriched for GO terms related to vital life cycle, innate immune response, positive regulation of immune response, defense response and response to stress (Fig. 3C) .
We furthermore investigated potential pathways STK32B is involved in. We identified proteins showing potential interactions with STK32B using GeneMANIA. As shown in Fig. 3B, STK32B has the ability to physically interact with zinc finger protein 217 (ZNF217), high mobility group 20B (HMG20B), PHD finger protein 21A (PHF21A) and REST corepressor 1 (RCOR1) proteins.
We could further confirm hypomethylation at cg16333992 using pyrosequencing in a subset of samples (n = 60), even though at this level of low methylation (0-2.5%), no methylation difference between individuals at high and low risk of GAD could be assessed.
Post-hoc analysis
Importantly, we further investigated methylation of STK32B in suicide risk under depression in two cortex regions. Two CpG sites were differentially methylated in the BA11 region, i.e. cg11768886 (p = 0.026, β = 3.17) and cg19764048 (p = 0.028, β = 4.52). For the second cortex region, B25, one CpG site was associated with a higher suicide risk, i.e. cg10351287 (p = 0.026, β = −0.96). The differentially methylated CpG site in relation to GAD risk in adolescents was close to significance in the B11 region (p = 0.066), showing higher methylation levels in controls compared to cases (β = −3.60). The negative trend at cg16333992 may be the result of the specific investigated prefrontal cortex area (B11) and the cumulative methylation changes associated with two complex neuropathogeneses, depression and suicide behavior.
Discussion
This is the first study investigating epigenome-wide DNA methylation in relation to GAD risk, focusing on positions for which methylation levels are predicted more by individual than by tissue. (Hannon et al., 2015) . We first compared blood methylation profiles of adolescents at high and low risk of GAD, and validated our result in an independent sample of adults taking anxiety medications. Then, we performed functional analysis of the identified gene using open-access data and bioinformatic tools. We found that methylation at cg16333992 (located within the promoter region of STK32B) is higher in adolescents at risk of GAD compared with their low-risk counterparts, and also higher in adults taking anti-anxiety medications compared with adults under no medication. This finding may be an indicator for the aspect that shifts in STK32B promoter-methylation may play a role in GAD pathogeny. This hypothesis is further supported by the fact that the detected methylation shifts were significantly associated with shifts in STK32B gene expression, supporting a functional relevance of the observed methylation differences.
The detected CpG site is located within the promoter of the STK32B (serine/threonine kinase 32B) gene. The STK32B protein is one of the human N-myristoylated proteins, which are known to play a role in different signaling and transduction pathways (Takamitsu et al., 2015) . Interestingly, we showed that brain methylation of the STK32B gene promoter was associated with suicidal behavior of depressed adults, further supporting our hypothesis of a relevant role of STK32B in psychiatric diseases. We observed an opposite effect of methylation shifts at the identified CpG, suggesting that blood is only partly reflecting the whole spectrum of methylation changes at this CpG site occurring in different brain regions. Recently, a study detected higher methylation levels in the body of STK32B in the dorsolateral prefrontal cortex (DLPFC) of schizophrenic patients compared with controls, using a methylome-wide study approach (Alelú-Paz et al., 2016) . The DLPFC is involved in executive functions including working memory and selective attention (Curtis and D'Esposito, 2003) . Importantly, Ochsner et al. showed that this region may influence emotional reactivity due to modulation of perceptual attention systems (Ochsner et al., 2012) . Additionally, given that the STK32B gene is expressed in hypothalamus, hippocampus, cerebral cortex and caudate (The human protein atlas, ), it can be hypothesized that methylation shifts within this gene may affect normal functioning of the DLPFC, a region that has been shown to be less active in anxious patients (Balderston et al., 2017) .
The function of STK32B is still unknown, but it has been shown to physically interact with PHF21A, a member of the BRAF-histone deacetylase repression complex (BHC), which is highly expressed in brain during neurodevelopment (Klajn et al., 2009; Hakimi et al., 2002) . Its paralog, PHF21B, was recently associated with major depression and might be involved in stress modulation (Wong et al., 2017) . Moreover, STK32B interacts with RCOR1 and HMG20B, which are part of the coREST (corepressor of repressor element-1-silencing transcription factor) complex (Hakimi et al., 2002) . CoREST was first described as a regulator of neuronal gene expression, through the modulation of chromatin structure (Andres et al., 1999) .
The methylation difference between adolescents at high and low risk of GAD was approximately 1%, which is consistent with previous studies that observed similar methylation differences in non-tumor tissues (Huang et al., 2015; Rijlaarsdam et al., 2016) . Importantly, Leenen et al., argued that methylation shifts (1-5%) could translate into major consequences for gene expression, especially in complex multifactorial conditions like depression or schizophrenia (Leenen et al., 2016) , further supporting a functional importance of our finding. In this context it is worth it to note that microarray techniques are a sensitive enough and therefore possible alternative for the determination of small methylation differences (0.5-10%) as observed in our study (Houtepen et al., 2016; Chambers et al., 2015; Huynh et al., 2014) . Chambers et al. e.g. identified differences of 0.5% to 1.1% between type 2 diabetes and controls, measured in whole blood with the Illumina 450K BeadChip (Chambers et al., 2015) .
It is particularly interesting that the top-hit genes were involved in the stress and defense response. These findings support the hypothesis that anxiety can be seen as an emotional state that stems from an adaptive response to stress (López et al., 2016) . Defense response is another natural adaptive reaction to stressful events, which may increase the likelihood to develop anxiety (Steimer, 2002) . Anxiety becomes pathological from the moment the stress response is altered and the defense response is activated in absence of an actual threat, or when the magnitude of these processes is higher than the actual danger. In line with this, identification of DNAm changes related to anxiety further supports involvement of epigenetic processes as a molecular substratum of adaptive ability and as putative mechanisms underlying dysfunctioning of neuropsychiatric systems in anxiety.
Importantly, our study approach considered the correlation between methylation shifts measured in blood and in brain, albeit not in the same individuals. Given that brain methylation cannot be studied in vivo in humans, we chose a novel approach analyzing only those methylation sites for which inter-individual variability was larger than inter-tissue variability. By restricting our analysis to these probes, we were able to obtain insights into shifts of brain methylation based on easily accessible DNA methylation levels measured in blood.
Limitations and future directions
First, the findings for this quite unique cohort of youth were replicated in an independent sample, with a limited number of adults obtaining anxiety treatment, which does not reflect the same set up of the discovery cohort (adolescents were not under anxiety treatment). Thus, we cannot exclude that the methylation shift at the identified CpG site may be also influenced by the treatment applied. Second, the methylation levels at the identified CpG site were in general very low in our study (3-9%) . This is most likely the reason why we were not able to confirm them with the pyrosequencing technique. The lower limit of detection for pyrosequencing has been observed to lie around 4% (Quillien et al., 2012) , which, thus, falls in the range of our observed methylation levels. However, studies have been using microarray technique for the determination of low levels of methylation (Wang et al., 2012; Emes and Wessely, 2012; Nicodemus-Johnson et al., 2016) . In line with this, we confirmed methylation changes in another sample, applying microarray and, thus, the same technique in the second cohort. Third, the effect size obtained in methylation expression analyses was small, pointing to only small transcriptional shifts associated with the CpG site in focus. However, the association between methylation shifts and expression changes was identified in an additional cohort that does not entirely reflect the original set up of the discovery and validation cohorts. Fourth, the blood-brain associations were tested in another cohort, focusing on neurodegenerative diseases.
Conclusions
In this study, we performed a robust DNA methylation analysis investigating the relationship between methylation shifts in whole blood and the risk of GAD in adolescents, focusing on positions for which inter-individual variability was larger than inter-tissue variability. Our findings suggest that a differential expression of STK32B due to methylation shifts may be a mechanism leading to increased GAD risk due to a changed interplay with other proteins, such as PHF21A known to be important for neurodevelopment in adolescence. Our results contribute to a better understanding of the molecular mechanisms underlying GAD development.
